Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler.

BACKGROUND

In many countries, two dry powder formulations of inhaled formoterol are available for clinical use; one uses a single-dose device (Foradil, Aerolizer), and the other uses a multiple-dose device (Oxis, Turbuhaler).

OBJECTIVES

To study the bronchodilating effect of formoterol 12 mg when delivered via the Aerolizer and Turbuhaler devices over 12 h.

STUDY DESIGN

Randomized, double-blind, placebo controlled crossover study. Forced expiratory volume in one second (FEV1) was monitored during a 12 h period.

PATIENTS

Nineteen nonsmoking asthma patients were included in the trial on the basis of reversibility of symptoms in response to inhaled salbutamol (either 200 or 400 mg given cumulatively; minimum reversibility 15%).

RESULTS

There were no significant differences between the two dry powder devices regarding the change from baseline of FEV1 over 12 h, the area under the curve of FEV1 over 12 h or the maximum value of FEV1. The improvement in FEV1 with formoterol 12 mg versus placebo was highly significant for both devices.

CONCLUSIONS

Formoterol is similarly effective when used as a dry powder when given by either Aerolizer or the Turbuhaler.